According to a new report Asia Pacific Biochips Market, published by KBV research, the Asia Pacific Biochips Market would witness market growth of 12.7% CAGR during the forecast period (2019-2025).
The China market dominated the Asia Pacific Hospitals and Diagnostics Centers Market by Country in 2018, growing at a CAGR of 9.9 % during the forecast period. The Japan market is expected to witness a CAGR of 13.2% during (2019 - 2025). Additionally, The India market is expected to witness a CAGR of 13.3% during (2019 - 2025).
The Drug Discovery and Development market dominated the South Korea Biochips Market by Application in 2018, growing at a CAGR of 12.9 % during the forecast period. The Disease Diagnostics market is expected to witness a CAGR of 12.8% during (2019 - 2025). The Genomics market is expected to witness a CAGR of 14.2% during (2019 - 2025).
The Lab-on-Chip market dominated the Malaysia Biochips Market by Product in 2018, and would continue to be a dominant market till 2025; growing at a CAGR of 14.1 % during the forecast period. The DNA Chip market is expected to witness a CAGR of 13.9% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/asia-pacific-biochips-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Fluidigm Corporation, Horiba Ltd., PerkinElmer, Inc., OriGene Technologies, Inc., Dynamic Biosensors GmbH, Illumina, Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Randox Laboratories Limited, Thermo Fisher Scientific, Inc.
ByProduct
By Application
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
